Robert Roby, MD
Internal Medicine · Baltimore, MDNPI 1508809971
Payments from drug & device makers
Across 149 payments — averaging $17.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$408
- Novo Nordisk$340
- GSK$245
- Sanofi-aventis U.S. LLC$172
- Pfizer$165
- Lilly USA, LLC$154
- plus $1K from 22 others
What the payments were for
- Food & beverage$2,60799%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 22 | $408 |
| Novo Nordisk | 19 | $340 |
| GSK | 15 | $245 |
| Sanofi-aventis U.S. LLC | 11 | $172 |
| Pfizer | 13 | $165 |
| Lilly USA, LLC | 8 | $154 |
| Exact Sciences | 5 | $117 |
| Merck | 9 | $110 |
| Sanofi Pasteur Inc. | 5 | $108 |
| Astellas Pharma US Inc | 5 | $98 |
| Novartis | 4 | $98 |
| Gilead | 5 | $91 |
| Amgen | 3 | $82 |
| AbbVie | 3 | $60 |
| E.r. Squibb & Sons, L.L.C. | 4 | $53 |
| Bayer | 2 | $45 |
| Aimmune Therapeutics, Inc. | 2 | $45 |
| Biogen | 2 | $41 |
| Sumitomo Pharma America, Inc. | 2 | $40 |
| Eisai Inc. | 1 | $34 |
| Johnson & Johnson | 2 | $25 |
| Dexcom, Inc. | 1 | $21 |
| Boehringer Ingelheim | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $14 |
| Acadia Pharmaceuticals Inc | 1 | $14 |
| Orexo US, Inc. | 1 | $12 |
| Hikma Pharmaceuticals USA | 1 | $11 |
How this compares
$2,639 in reported general payments places this provider in the 80th percentile of 2,979 internal medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 157 | $174,542 |
| JardianceEmpagliflozin | 127 | $152,241 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 82 | $90,567 |
| JanuviaSitagliptin Phosphate | 54 | $63,205 |
| Breo ElliptaFluticasone/Vilanterol | 78 | $45,699 |
| TrulicityDulaglutide | 21 | $45,581 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 11 | $42,044 |
| OzempicSemaglutide | 45 | $40,399 |
| MounjaroTirzepatide | 21 | $33,369 |
| FarxigaDapagliflozin Propanediol | 24 | $32,252 |
| EntrestoSacubitril/Valsartan | 21 | $28,087 |
| OxycontinOxycodone Hcl | 28 | $27,484 |
| XareltoRivaroxaban | 12 | $18,959 |
| MyrbetriqMirabegron | 25 | $16,884 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 22 | $14,784 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $165 | $174,542157 claims |
| Boehringer IngelheimJardiance, Tradjenta | $20 | $161,594140 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $245 | $136,266160 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $154 | $78,95042 claims |
| MerckJanuvia | $110 | $63,20554 claims |
| Novo NordiskOzempic, Rybelsus | $340 | $54,39556 claims |
| GileadBiktarvy | $91 | $42,04411 claims |
| AstraZenecaFarxiga | $408 | $32,25224 claims |
| NovartisEntresto | $98 | $28,08721 claims |
| Johnson & JohnsonXarelto | $25 | $18,95912 claims |
| Astellas Pharma US IncMyrbetriq | $98 | $16,88425 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone | $11 | $5,71237 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,979 internal medicine providers in Maryland.
Other internal medicine in Baltimore
- Kristen MarroneBaltimore$5.6M
- Peta-Gay Jackson BoothBaltimore$3.6M
- Mark YarchoanBaltimore$2.4M
- Gabrielle PrinceBaltimore$2.1M
- Jessica TaoBaltimore$1.2M
- Ana-Maria OrbaiBaltimore$1.1M
- Julie PaikBaltimore$1M
- Christopher MelaniBaltimore$997K
- Ethel WeldBaltimore$792K
- Christian GockeBaltimore$725K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.